Edition:
India

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

3.87USD
2:29am IST
Change (% chg)

$-0.09 (-2.27%)
Prev Close
$3.96
Open
$4.00
Day's High
$4.02
Day's Low
$3.80
Volume
178,808
Avg. Vol
157,814
52-wk High
$4.28
52-wk Low
$0.88

Chart for

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip... (more)

Overall

Beta: --
Market Cap(Mil.): $57.61
Shares Outstanding(Mil.): 27.70
Dividend: --
Yield (%): --

Financials

BRIEF-Sphera Funds Management Ltd Reports 7.43 Pct Passive Stake In Viking Therapeutics

* SPHERA FUNDS MANAGEMENT LTD REPORTS 7.43 PERCENT PASSIVE STAKE IN VIKING THERAPEUTICS INC AS OF DECEMBER 7 - SEC FILING Source text : http://bit.ly/2kdgndu Further company coverage:

18 Dec 2017

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

06 Dec 2017

BRIEF-Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture

* VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VK5211 IN PATIENTS RECOVERING FROM HIP FRACTURE

28 Nov 2017

BRIEF-Viking Therapeutics reports third quarter 2017 financial results

* Viking Therapeutics reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Viking Therapeutics files for sale of up to 6.9 mln shares by selling stockholder

* Viking Therapeutics Inc files for sale of up to 6.9 million shares of co's common stock by selling stockholder Lincoln Park Capital Fund Llc‍‍​ - SEC filing Source text: (http://bit.ly/2x3eVPr) Further company coverage:

18 Oct 2017

BRIEF-VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214

* VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214 IN IN VIVO MODEL OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD)

04 Oct 2017

BRIEF-VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

* VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

29 Sep 2017

BRIEF-Viking Therapeutics Q2 loss per share $0.21

* Viking Therapeutics reports second quarter 2017 financial results and provides corporate update

10 Aug 2017

BRIEF-Viking Therapeutics completes enrollment in Phase 2 study of VK5211

* Viking Therapeutics completes enrollment in Phase 2 study of VK5211 in patients recovering from hip fracture

12 Jul 2017

BRIEF-Viking therapeutics appoints Charles A. Rowland Jr. to board

* Viking Therapeutics appoints Charles A. Rowland Jr. to board of directors Source text for Eikon: Further company coverage:

06 Jul 2017

Earnings vs. Estimates